A single oral compound advancing across four indications: retinal degeneration first, CNS neurodegeneration next.
SBC003 is SunRegen's first-in-class orally bioavailable lipid therapeutic. Its mutation-agnostic mechanism, inducing neuroglobin expression via p-body modulation, enables a platform strategy across multiple neurodegenerative indications with a single compound.
SBC003 is investigational and has not been approved by any regulatory authority. This page presents scientific and development-stage information only.
All four programs use SBC003 orally administered, eliminating the need for intravitreal injections required by current retinal therapies.
Development Stage
Development Stage
Development Stage
Development Stage
The combined addressable market across SBC003's four lead indications exceeds $70 billion by 2034. The neurodegenerative therapeutics market, currently $45–52B, is growing at 5.7–7.2% CAGR driven by aging demographics and the utter failure of the one-target drug paradigm.
Market Size
$3.8B by 2034
Growth
12.1% CAGR
Patients
2M globally
Unmet need: 99% have no disease-modifying treatment
Market Size
$7.9B by 2032
Growth
9.3% CAGR
Patients
200M globally
Unmet need: No approved oral treatment; EMA rejected both approved injectables
Market Size
$5.9B by 2034
Growth
8.8% CAGR
Patients
~2M in US/EU/China/Japan
Unmet need: No approved neuroprotective treatment
Market Size
$45–52B today → $70B+ by 2034
Growth
5.7–7.2% CAGR
Patients
32–38M Alzheimer's, 10M Parkinson's, globally
Unmet need: No approved disease-modifying therapy across all major CNS indications. The one-target drug paradigm has structurally failed.
No other compound in development combines oral bioavailability, broad-spectrum neuroprotection, and retinal + CNS potential in a single molecule.
Oral Administration
SBC003 is a simple, daily pill.
Mutation-agnostic
Targets the universal neuronal apoptosis pathway downstream of any mutation. Applicable to 100% of RP patients vs. <1% eligible for gene therapies like Luxturna.
Five-protein shield
Published evidence of protection against all five major neurotoxic proteins, amyloid-β, α-synuclein, tau, prion, and amylin, in a single peer-reviewed Aging Cell paper.
Validated in primates
Significant RNFL recovery in rhesus monkeys with naturally occurring optic atrophy at oral doses of 5–50 mg/kg. Plasma concentrations of 47.6–86.4 ng/mL confirmed.
Understand the mechanism of action, preclinical data, and the peer-reviewed evidence supporting SBC003.
Pioneering first-in-class orally bioavailable lipid therapeutics to halt neurodegeneration and restore vision. Clinical-stage. Basel, Switzerland.
© 2026 SunRegen Healthcare AG. All rights reserved.
Business Parc Reinach, Christoph Merian-Ring 11, 4153 Reinach, Switzerland
UID: CHE-295.245.274
This website contains forward-looking statements regarding future products, development plans, and business strategies. Actual results may differ materially. Nothing on this site constitutes medical or investment advice.